Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial.

Abstract

BACKGROUND The irreversible ErbB family blocker afatinib and the reversible EGFR tyrosine kinase inhibitor gefitinib are approved for first-line treatment of EGFR mutation-positive non-small-cell lung cancer (NSCLC). We aimed to compare the efficacy and safety of afatinib and gefitinib in this setting. METHODS This multicentre, international, open-label… (More)
DOI: 10.1016/S1470-2045(16)30033-X

Topics

Cite this paper

@article{Park2016AfatinibVG, title={Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial.}, author={Keunchil Park and E. Tan and Ken O'Byrne and Li Zhang and Michael Boyer and Tony C. W. Mok and Vera Hirsh and James C Yang and Ki Hyeong Lee and Shun Lu and Yuankai Shi and Sang-We Kim and Janessa Laskin and Dong-Wan Kim and Catherine Dubos Arvis and Karl Gustav K{\"o}lbeck and Scott A. Laurie and Chun-Ming Tsai and Mehdi Shahidi and Miyoung Kim and Dan Massey and Victoria Zazulina and Luis Paz-Ares}, journal={The Lancet. Oncology}, year={2016}, volume={17 5}, pages={577-89} }